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Methods
Study Participants
CAA participants were recruited as part of a single-center prospective cohort study, FAVR, designed to investigate vascular reactivity changes in CAA. 4 The participants were recruited from a stroke prevention clinic or memory clinic. Participants were assessed >90 days after symptomatic ICH to avoid confounding effects of acute ICH. Eligibility was based on presentation with a CAA-related syndrome (ICH, cognitive symptoms without dementia, CAA-related inflammation, or transient focal neurological symptoms) accompanied by a pattern of lobar-only cerebral microbleeds (CMBs) and superficial siderosis consistent with probable CAA according to modified Boston criteria 5 or criteria for CAA-related inflammation. 6 The patients with CAA-related inflammation were studied during remission, at a time when no vasogenic edema was visible on magnetic resonance imaging (MRI) fluid-attenuated inversion recovery. To reduce the confounding effects of concomitant AD pathology, CAA patients with dementia (according to Diagnostic and Statistical Manual-IV criteria) were excluded. CAA participants had to be living in the community and not a long-term care facility, without aphasia or visual field deficits.
AD-dementia patients were recruited from the memory clinic and were diagnosed based on National Institute on Aging-Alzheimer's Association criteria for clinical probable AD. 7 They had relatively mild-stage AD-dementia, based on requirements for the Folstein Mini-Mental Status Examination 8 score to be ≥20 and to be living in the community and not a long-term care facility.
MCI participants were recruited from the memory clinic or via community advertising as part of a separate cohort study with harmonized neuropsychological testing (Imaging and Neuropsychological Assessment of Cognitive Impairment [IMPACT] ). They were diagnosed using National Institute on Aging-Alzheimer's Association criteria. 9 IS controls were recruited as part of the Computed Tomography and MRI in the Triage of TIA and Minor Cerebrovascular Events to Identify High Risk Patients (CATCH) study. 10 Patients presented within 24 hours and had mild severity (National Institutes of Health Stroke Scale score ≤3). Infarction was confirmed by MRI diffusionweighted imaging. Stroke subtype was determined according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria.
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For all groups, participants were excluded if they were not fluent in English, were <60 years old, were so cognitively impaired that they lacked capacity to provide informed consent, had a history of other structural cerebral disorders or psychosis, actively abused substances, or had contraindications to MRI. AD, MCI, and IS participants were excluded if MRI susceptibility-weighted imaging or T2*-weighted gradient-recalled echo showed a pattern of lobar-only microbleeds suggestive of CAA.
Study participants provided written informed consent to participate. The study was approved by the University of Calgary institutional review board.
Assessments
Neuropsychological assessment was based on the test battery proposed by the National Institute for Neurological Diseases and Stroke-Canadian Stroke Network 12 and included Trail Making A (TMT-A) and B (TMT-B), 13 Controlled Oral Word Association Test-FAS (COWAT-FAS), 14 Digit Symbol Coding (DSC) subtest of the WAIS-IV, 15 Rey-Osterrieth Complex Figure Test (ROCFT), 16 and verbal learning and memory (California Verbal Learning Test: Second Edition [CVLT-II]). 17 The presence or absence of clinical cognitive concerns was assessed by interview of the patient and a close informant using questions developed by Jessen et al. 18 MRI was performed on a 3.0T Signa VH/I or MR750 (General Electric Healthcare, Waukesha, WI). Sequence parameters are provided in Methods in Table I in the online-only Data Supplement. WMH volumes were measured using Quantomo (Cybertrials, Inc, Calgary, Canada), a custom-designed software application. 4 WMH volumes were expressed as a fraction of intracranial volume and are presented in cm 3 relative to a typical intracranial volume of 1448.9 cm 3 to account for differences in head size, as in past studies. 19 Good measurement reliability was demonstrated on measurement of 30 CATCH participants by 3 independent raters, with intraclass correlation coefficients 0.98 for inter-rater and 0.98 to 0.99 for intrarater reliability. CMBs and superficial siderosis, as defined by consensus criteria, 20 were determined on susceptibility-weighted imaging by a single rater. The percent of blood oxygen level-dependent (BOLD) response in the visual cortex was determined using functional MRI (fMRI) during a visual stimulation task, as previously described. 4 MRI data were missing from 2 participants because of claustrophobia, and 1 participant did not have susceptibility-weighted imaging.
Blood was processed for APOE genotype using the restriction fragment length polymorphism method. 21 IS participants of CATCH study did not have APOE genotype measured, and APOE genotype was missing for 12/119 (10%) of nonstroke participants because the participants declined or the sample could not be processed.
Statistical Analyses
Participant characteristics were tabulated and compared with those of the CAA group using t test, Wilcoxon rank-sum test, or χ 2 test, as appropriate. There were no missing data except as noted in the preceding sections. Neuropsychological test scores were converted to z scores, adjusting for age, sex, and education, according to the normative data in the test manuals. Differences from published norms were tested using the 1-sample t test. We analyzed tests grouped into 3 domains: episodic memory (average of the delayed recall portions of the CVLT-II and ROCFT), executive function (average of the TMT-B and COWAT-FAS), and perceptual and processing speed (average of the DSC and TMT-A). For the purposes of this study, a mean z score of ≤−1.00 was taken to indicate cognitive impairment. Differences in z score means between CAA and the comparison patient groups were tested using general linear models, with Dunnett-Hsu's test to control for post hoc comparisons between CAA and each of the comparator groups. Models were adjusted for age, sex, and education. To test whether there were associations between either WMH or the presence of ≥1 APOE ε4 allele (potential predictors) and neuropsychological test scores (outcomes), general linear models were repeated with terms for WMH or APOE (in separate models) and their interaction with disease group. If either main effects or their interactions were significant, then the association of the predictor with the outcome was reported for CAA. Associations between cognitive domain scores, CMB count, and fMRI BOLD responses in CAA were tested using general linear models controlling for age, sex, and education. Analyses were done using SAS version 9.3 (SAS Institute, Cary, NC). P values were 2-tailed and were considered significant if <0.05.
Results
There were 34 CAA, 16 AD-dementia, 69 MCI, and 27 IS participants (Table 1) . Seventeen (50%) of the CAA participants presented with ICH, whereas the remainder presented with either inflammation (n=3), cognitive symptoms (n=5), or transient focal neurological episodes (n=9). Locations of ICHs and infarcts are shown in Table II in the online-only Data Supplement. In CAA participants, the median CMB count was 20 (interquartile range 5-58), 12/31 (38.7%) had cortical superficial siderosis, and mean fMRI BOLD amplitude response was 1.93% (standard deviation 0.79%). National Institutes of Health Stroke Scale scores did not differ between CAA with ICH and IS participants (P=0.43). CAA participants were older than IS participants, more likely to have hypertension than AD-dementia participants, had fewer years of education than AD-dementia participants, and had higher WMH volumes than all the comparison groups.
Test scores without adjustment are provided in Results in Table III in the online-only Data Supplement. Table 2 shows
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test scores expressed as z scores based on published age-, education-, and sex-adjusted means (from the published testing manuals). CAA participants scored significantly below zero on all tests except the CVLT-DR and below zero in all domain scores. In CAA, executive function and processing speed were more severely impaired than memory, whereas in the other groups, executive function and memory scores were not significantly different within participants (Figure 1 ). Most CAA participants (27/34, 79%) had clinical cognitive concerns along with ≥1 test scores <−1.0 SD from the normative mean, indicating that they met criteria for MCI. Estimated cognitive domain means with 95% confidence limits from general linear models adjusting for age, sex, and education, with comparisons between the adjusted means between CAA and each of the control groups, are shown in Figure 2 and tabulated in Table IV in the online-only Data Supplement. CAA participants performed better on episodic memory than AD-dementia participants but similar on executive function and processing speed (although performance was significantly below zero for all domains). CAA participants had similar episodic memory and executive function but worse processing speed than MCI participants. Compared with IS, CAA participants performed worse on executive function and processing speed.
WMH volumes varied by patient group, with CAA participants having the highest WMH volumes (Table 1) . Multivariable models adjusting for patient group, age, education, sex, and WMH by group interaction showed that there was an interaction between WMH and group for processing speed (P=0.04). Consequently, we examined the relationships between WMH and processing speed in CAA alone, in fully adjusted models, and found that higher WMH was associated with slower processing speed, such that for each 10% increase in WMH, the estimated processing speed z score was 0.04 lower (95% confidence limits −0.001, −0.07; P=0.04). WMH volume was not associated with the executive function or episodic memory domains in the adjusted models.
CMB counts were not correlated with cognitive domain scores in CAA participants (memory: r=0.06, P=0.76; executive function: r=−0.20, P=0.28; processing speed: r=−0.03, P=0.89). The presence or absence of superficial siderosis was also not associated with mean cognitive domain scores in CAA participants (P≥0.20 for each comparison). Visual fMRI BOLD responses tended to be lower in participants with slower processing speed, but this difference was not significant (0.46 lower z score for each 1% lower visual BOLD response; 95% confidence limits 0.07, −0.99; P=0.09).
There was no association between APOE ε4 and either episodic memory, executive function, or processing speed (P>0.10 for all associations).
Five CAA participants presented with MCI without ICH, CAA-related inflammation, or transient focal neurological symptoms. When analyses were repeated excluding these participants, the same significant relationships were observed (Tables V and VI in the online-only Data Supplement).
Discussion
The main finding of this study is that most nondemented patients with clinically diagnosed CAA meet criteria for MCI, performing significantly worse on neuropsychological tests of executive functioning, perceptual speed, and episodic memory compared with normative values.
Mean test performance in CAA was similar to that of a cohort of participants with amnestic or nonamnestic MCI. Compared with participants with mild AD-dementia, CAA patients had similarly impaired performance on processing speed, somewhat better performance on executive function, and much better performance on episodic memory. These results suggest that CAA is associated with a cognitive profile of impaired processing speed and executive dysfunction, distinct from the typical AD profile where episodic memory is also severely impaired. The CAA-associated cognitive profile is therefore more consistent with the profile of vascular cognitive impairment. 22 Processing speed and executive function were worse in CAA than in stroke IS controls, suggesting that CAA may be more closely associated with vascular cognitive impairment than other causes of stroke.
Our results complement the findings of community-based autopsy studies, which show CAA pathology is associated with worse cognitive performance and risk for dementia during life. In the Religious Orders studies, participants with CAA had worse performance in cognitive domains of perceptual speed and episodic memory at the last assessment before death 23 and exhibit greater declines in global cognition, perceptual speed, episodic memory, and semantic memory before death, as well as an increased risk for dementia. 3 In the population-based Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS), CAA at autopsy was associated with increased risk for dementia during life, 24 accounting for 7% of the population-attributable risk. 25 In the Honolulu-Asia Aging Study (HAAS), CAA was associated with worse global cognitive performance but only in men who also had AD pathology. 26 In each case, AD pathology was concurrently measured and controlled for in statistical models; therefore, these CAA associations were independent of AD pathology (with which it is moderately correlated). Unfortunately, there is no in vivo biomarker that can discriminate vascular amyloid (CAA) from parenchymal amyloid plaques 27 ; therefore, participants in our study did not have amyloid imaging or cerebrospinal fluid analysis.
Pathological scoring systems for CAA and analytic strategies varied across the autopsy studies, but moderate to severe CAA pathology was described in 20% to 36% of relatively unselected community-dwelling elderly, 3, 23, 24, 26 the vast majority of whom would not be expected to have had a CAArelated clinical syndrome. Our study data complement these autopsy studies of clinically unrecognized CAA pathology by showing that a CAA cognitive profile can be identified in living patients. Our literature reviews found only one other paper which systematically assessed neuropsychological test performance in living CAA patients. 28 Concordant with our findings, processing speed and executive function were the most impaired compared with controls. 28 We extend on these prior findings by providing the first comparisons with AD, MCI, and IS patients. Our findings may be generalized to living patients with CAA-related syndromes; however, in our study, we may have underestimated the severity of cognitive impairment in symptomatic CAA patients because we excluded CAA patients with dementia, aphasia, or visual field deficits, and many CAA patients with ICH do not survive or have severe disabilities and therefore would either not meet eligibility criteria for our study or potentially be less likely to participate.
The mechanistic basis of cognitive impairment in CAA is unclear. CAA has been associated with WMH, microinfarcts, and microbleeds, 1 all of which have been implicated as a cause of cognitive impairment in other settings. [29] [30] [31] A prior study of lobar ICH patients showed that higher WMH was associated with a history of pre-ICH cognitive impairment. 32 In the Religious Orders studies, the association between CAA and cognitive impairment was not mediated by microinfarcts. 3 In the present study, higher WMH and lower fMRI BOLD responses were associated with worse processing speed, but we did not identify variables that were associated with the impaired executive function or episodic memory seen in CAA. Therefore, other mechanisms not accounted for in this study must also be contributing to cognitive impairment in CAA. Superficial siderosis and CMB counts were not correlated with neuropsychological test scores, suggesting that ischemic changes are probably more relevant for cognitive impairment than hemorrhagic changes. More studies will be needed to clarify the relationship between impaired vascular reactivity, WMH, and processing speed, including the timing of appearance of impaired vascular reactivity and WMH and how they disrupt brain network connectivity. 33 The APOE ε4 allele is associated with CAA, independent of AD pathology. 34 The APOE ε4 allele was found in 62% of our CAA cases, similar to AD and higher than the expected prevalence in the community (≈20%). 35 However, we did not find that CAA, AD-dementia, or MCI participants with APOE ε4 had a different cognitive profile than participants without APOE ε4. The APOE ε4 allele may be a risk factor for CAA but not a modifier of cognitive outcomes within CAA.
Study strengths include relevant comparison groups with AD-dementia and stroke patient groups. However, there are also limitations. The sample sizes are relatively small, and we lacked power to detect small differences from normative data or moderate differences between groups. Future larger studies will be needed to determine whether cognitive profiles are different in CAA subgroups defined by presenting syndrome. Other studies could also investigate other cognitive domains, such as attention, working memory, language, and visuospatial abilities. Biomarkers of the AD pathophysiological process, such as amyloid imaging or CSF analyses, were not part of the study. Future studies should determine whether amyloid marker load is associated with cognitive impairment in CAA. However, these biomarkers would not have discriminated CAA from AD. Amyloid-binding ligands for positron emission tomographic studies bind with high affinity to either parenchymal or vascular Aβ, making them useless for discriminating AD from CAA pathology. 27 To identify a more specific CAA cognitive profile, we excluded patients with dementia who may also have had AD. Future studies will be needed to identify cognitive trajectories in CAA, including the risk for progression to dementia and what type of dementia results. Finally, future studies should evaluate the prevalence of depression in CAA and its relationship to cognitive performance.
This study suggests that patients clinically diagnosed with CAA frequently have cognitive impairment with relatively preserved episodic memory that would be unusual for AD, implying vascular mechanisms of impairment. Patients diagnosed with CAA should be screened by history for symptoms of cognitive impairment, with cognitive screening and neuropsychological testing as indicated depending on the level of symptoms and concern. CAA is a cerebrovascular disorder with a high risk of cognitive impairment. Even though disease-modifying treatments for CAA are not available, supportive care and, in patients with recent ICH, cognitive rehab may maximize function and enhance recovery. Processing speed -1.08±1.14 <0.001
Within participants, scores on executive function were significantly lower than memory (p=0.02).
